Donald A. Tomalia is presently Director of the National Dendrimer and Nanotechnology Center and Founder/President of NanoSynthons, LLC. He is internationally recognized as a pioneer in dendrimers, dendritic polymers, dendrimer-based nanomedicine and a new nano-periodic system for defining and unifying nanoscience. Active in both academia and industry, Tomalia is an Associate Editor of Nanomedicine (Elsevier), the founder of several dendrimer production companies including, most recently, NanoSynthons, LLC (2010) and Dendritic Nanotechnologies, Inc. (2001), a subsidiary of Starpharma.
Inhaltsangabe
1. Introduction 2. The dendritic state 3. Synthetic methodologies 4. Characterization methodologies 5. Biopharmaceutical applications and products 6. Toxicology of dendrimers and dendrons 7. The dendritic effect 8. Dendrons and dendrimers: quantized dendritic building blocks leading to a new nano-periodic system 9. The past, present and future for dendrimers and dendrons.
1. Introduction 2. The dendritic state 3. Synthetic methodologies 4. Characterization methodologies 5. Biopharmaceutical applications and products 6. Toxicology of dendrimers and dendrons 7. The dendritic effect 8. Dendrons and dendrimers: quantized dendritic building blocks leading to a new nano-periodic system 9. The past, present and future for dendrimers and dendrons.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
